PATENT CLAIM ANALYSIS

Application Number: 15928123
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "085600"]

Abstract:
The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.

Claim (Index 1):
A method of treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis comprising administering IFN-\u03b2 in combination with cladrabine, wherein Cladribine is orally administered following the sequential steps below:\n (i) An induction period wherein Cladribine is administered and wherein the total dose of Cladribine reached at the end of the induction period is from about 1.7 mg/kg to about 3.5 mg/kg; \n (ii) A Cladribine-free period wherein no Cladribine is administered; \n (iii) A maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); and \n (iv) A Cladribine-free period wherein no Cladribine is administered.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.17241
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12301083', '11722018', '12766173', '09904263', '15032919']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7394588312481246
- 35 USC 102 Novelty (BERT): 0.5597078511082644
- Combined Prediction Score: 0.7214837332341386
- Mean Citation Score: 317.2390000000001
- Max Citation Score: 446.3266
- Similarity Product: 362.90479769616127

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test